Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis.

Edwards CJ, Bukowski JF, Burns SM, Jones HE, Pedersen R, Sopczynski J, Marshall L.

Drugs Aging. 2020 Jan;37(1):35-41. doi: 10.1007/s40266-019-00721-5.

PMID:
31712995
2.

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.

Wang EQ, Bukowski JF, Yunis C, Shear CL, Ridker PM, Schwartz PF, Baltrukonis D.

BioDrugs. 2019 Oct;33(5):571-579. doi: 10.1007/s40259-019-00375-0.

3.

Efficacy and Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis: A Post-Hoc Analysis of Randomized Controlled Trials.

Edwards CJ, Roshak K, Bukowski JF, Pedersen R, Thakur M, Borlenghi C, Curiale C, Jones H, Marshall L.

Drugs Aging. 2019 Sep;36(9):853-862. doi: 10.1007/s40266-019-00691-8.

PMID:
31292906
4.

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.

Foeldvari I, Constantin T, Vojinović J, Horneff G, Chasnyk V, Dehoorne J, Panaviene V, Sušić G, Stanevicha V, Kobusinska K, Zuber Z, Dobrzyniecka B, Nikishina I, Bader-Meunier B, Breda L, Doležalová P, Job-Deslandre C, Rumba-Rozenfelde I, Wulffraat N, Pedersen RD, Bukowski JF, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Arthritis Res Ther. 2019 May 23;21(1):125. doi: 10.1186/s13075-019-1916-9.

5.

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, Stempora L, Hammond C, Wouters A, Mojcik CF, Cheng J, Collinge M, Jesson MI, Hazra A, Biswas P, Lan S, Clark JD, Hodge JA.

Clin Immunol. 2018 Jun;191:10-20. doi: 10.1016/j.clim.2018.03.002. Epub 2018 Mar 5.

6.

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis.

Dougados M, Maksymowych WP, Landewé RBM, Moltó A, Claudepierre P, de Hooge M, Lambert RG, Bonin R, Bukowski JF, Jones HE, Logeart I, Pedersen R, Szumski A, Vlahos B, van der Heijde D.

Ann Rheum Dis. 2018 Feb;77(2):221-227. doi: 10.1136/annrheumdis-2017-212008. Epub 2017 Sep 29.

7.

Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis.

Maksymowych WP, Wichuk S, Dougados M, Jones HE, Pedersen R, Szumski A, Marshall L, Bukowski JF, Lambert RG.

Ann Rheum Dis. 2018 Jan;77(1):78-84. doi: 10.1136/annrheumdis-2017-211605. Epub 2017 Sep 29.

8.

MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation.

Maksymowych WP, Wichuk S, Dougados M, Jones H, Szumski A, Bukowski JF, Marshall L, Lambert RG.

Arthritis Res Ther. 2017 Jun 6;19(1):126. doi: 10.1186/s13075-017-1342-9.

9.

Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.

Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, van den Bosch F, Wei JC, Pedersen R, Bonin R, Jones H, Marshall L, Logeart I, Vlahos B, Bukowski JF, Maksymowych WP.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1590-1598. doi: 10.1002/acr.23276. Epub 2017 Aug 31.

10.

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.

Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Van den Bosch F, Logeart I, Wajdula J, Jones H, Marshall L, Bonin R, Pedersen R, Vlahos B, Kotak S, Bukowski JF.

Ann Rheum Dis. 2016 Jul;75(7):1328-35. doi: 10.1136/annrheumdis-2015-207596. Epub 2015 Aug 12.

11.

The burden of non-radiographic axial spondyloarthritis.

Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, Vlahos B, Kotak S.

Semin Arthritis Rheum. 2015 Apr;44(5):556-562. doi: 10.1016/j.semarthrit.2014.10.009. Epub 2014 Oct 22. Review.

PMID:
25532945
12.

Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.

Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF.

Arthritis Rheumatol. 2014 Aug;66(8):2091-102. doi: 10.1002/art.38721.

13.

Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations.

Attur M, Wang HY, Kraus VB, Bukowski JF, Aziz N, Krasnokutsky S, Samuels J, Greenberg J, McDaniel G, Abramson SB, Kornman KS.

Ann Rheum Dis. 2010 May;69(5):856-61. doi: 10.1136/ard.2009.113043. Epub 2009 Nov 23.

14.

Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study.

Nantz MP, Rowe CA, Bukowski JF, Percival SS.

Nutrition. 2009 Feb;25(2):147-54. doi: 10.1016/j.nut.2008.07.018. Epub 2008 Oct 9.

PMID:
18848434
15.

L-theanine intervention enhances human gammadeltaT lymphocyte function.

Bukowski JF, Percival SS.

Nutr Rev. 2008 Feb;66(2):96-102. doi: 10.1111/j.1753-4887.2007.00013.x. Review.

PMID:
18254876
16.

Bioactive food components that enhance gammadelta T cell function may play a role in cancer prevention.

Percival SS, Bukowski JF, Milner J.

J Nutr. 2008 Jan;138(1):1-4. Review.

PMID:
18156395
18.

Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement.

Solomon DH, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS.

Arthritis Rheum. 2006 Dec 15;55(6):873-7.

19.

Alternative bisphosphonate targets and mechanisms of action.

Bukowski JF, Dascher CC, Das H.

Biochem Biophys Res Commun. 2005 Mar 18;328(3):746-50. Review.

PMID:
15694409
20.

Identification of guinea pig gammadelta T cells and characterization during pulmonary tuberculosis.

Xiong X, Morita CT, Bukowski JF, Brenner MB, Dascher CC.

Vet Immunol Immunopathol. 2004 Nov;102(1-2):33-44.

PMID:
15451613
21.

Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses.

Kamath AB, Wang L, Das H, Li L, Reinhold VN, Bukowski JF.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):6009-14. Epub 2003 Apr 28.

22.

Conservation of nonpeptide antigen recognition by rhesus monkey V gamma 2V delta 2 T cells.

Wang H, Lee HK, Bukowski JF, Li H, Mariuzza RA, Chen ZW, Nam KH, Morita CT.

J Immunol. 2003 Apr 1;170(7):3696-706.

24.
25.

Antibacterial effect of human V gamma 2V delta 2 T cells in vivo.

Wang L, Kamath A, Das H, Li L, Bukowski JF.

J Clin Invest. 2001 Nov;108(9):1349-57.

26.

Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.

Das H, Wang L, Kamath A, Bukowski JF.

Blood. 2001 Sep 1;98(5):1616-8.

PMID:
11520816
27.

MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function.

Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, Bukowski JF.

Immunity. 2001 Jul;15(1):83-93.

28.

T cell receptor-dependent activation of human lymphocytes through cell surface ganglioside GT1b: implications for innate immunity.

Bukowski JF, Roncarolo MG, Spits H, Krangel MS, Morita CT, Brenner MB, Band H.

Eur J Immunol. 2000 Nov;30(11):3199-206.

29.

Recognition of nonpeptide prenyl pyrophosphate antigens by human gammadelta T cells.

Morita CT, Lee HK, Leslie DS, Tanaka Y, Bukowski JF, Märker-Hermann E.

Microbes Infect. 1999 Mar;1(3):175-86. Review. No abstract available.

PMID:
10801228
30.

Recognition of nonpeptide prenyl pyrophosphate antigens by human gammadelta T cells

Morita CT, Lee HK, Leslie DS, Tanaka Y, Bukowski JF, Marker-Hermann E.

Microbes Infect. 1999 Mar;1(3):175-86. No abstract available.

PMID:
10594981
31.
32.
33.

Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells.

Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, Bloom BR, Golan DE, Brenner MB.

Immunity. 1995 Oct;3(4):495-507.

34.

V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer.

Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H.

J Immunol. 1995 Feb 1;154(3):998-1006.

PMID:
7529807
35.

Recognition and destruction of virus-infected cells by human gamma delta CTL.

Bukowski JF, Morita CT, Brenner MB.

J Immunol. 1994 Dec 1;153(11):5133-40.

PMID:
7963571
36.

Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes.

Bukowski JF, Kurane I, Lai CJ, Bray M, Falgout B, Ennis FA.

J Virol. 1989 Dec;63(12):5086-91.

37.

Antiviral effect of lymphokine-activated killer cells: chemotaxis and homing to sites of virus infection.

Natuk RJ, Bukowski JF, Brubaker JO, Welsh RM.

J Virol. 1989 Nov;63(11):4969-71.

38.
39.

The role of interferon in the regulation of virus infections by cytotoxic lymphocytes.

Welsh RM, Yang H, Bukowski JF.

Bioessays. 1988 Jan;8(1):10-3. Review. No abstract available.

PMID:
2452630
40.

Natural killer cells are not required for interferon-mediated prophylaxis against vaccinia or murine cytomegalovirus infections.

Bukowski JF, McIntyre KW, Yang H, Welsh RM.

J Gen Virol. 1987 Aug;68 ( Pt 8):2219-22.

PMID:
3039047
42.
44.

Exquisite specificity of adoptive immunization in arenavirus-infected mice.

McIntyre KW, Bukowski JF, Welsh RM.

Antiviral Res. 1985 Oct;5(5):299-305.

PMID:
3877492
45.

Expression of asialo GM1 and other antigens and glycolipids on natural killer cells and spleen leukocytes in virus-infected mice.

Yang H, Yogeeswaran G, Bukowski JF, Welsh RM.

Nat Immun Cell Growth Regul. 1985;4(1):21-39.

PMID:
3875791
46.

Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo.

Bukowski JF, Warner JF, Dennert G, Welsh RM.

J Exp Med. 1985 Jan 1;161(1):40-52.

47.
48.
49.

Role of natural killer cells in virus infections of mice.

Welsh RM, Biron CA, Bukowski JF, McIntyre KW, Yang H.

Surv Synth Pathol Res. 1984;3(5):409-31. Review. No abstract available.

PMID:
6084280
50.

Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo.

Bukowski JF, Woda BA, Habu S, Okumura K, Welsh RM.

J Immunol. 1983 Sep;131(3):1531-8.

PMID:
6309965

Supplemental Content

Loading ...
Support Center